Quick Answer
Actinium Pharmaceuticals, Inc. reported Operating Income Loss of -$36.25 million for the year ending 2025.
- Actinium Pharmaceuticals, Inc. showed an increase of +13.9% in Operating Income Loss from 2024 to 2025.
- This data is from Actinium Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: -$839.3 thousand | Q3 2012: -$2.40 million | Q1 2013: -$2.02 million | Q2 2013: -$1.48 million | Q3 2013: -$1.61 million | Q1 2014: -$4.14 million | Q2 2014: -$4.42 million | Q3 2014: -$7.04 million | Q1 2015: -$7.87 million | Q2 2015: -$7.40 million | Q3 2015: -$4.64 million | Q1 2016: -$6.00 million | Q2 2016: -$6.92 million | Q3 2016: -$7.10 million | Q1 2017: -$7.81 million | Q2 2017: -$7.20 million | Q3 2017: -$6.70 million | Q1 2018: -$6.35 million | Q2 2018: -$4.91 million | Q3 2018: -$6.20 million | Q1 2019: -$5.70 million | Q2 2019: -$5.09 million | Q3 2019: -$6.65 million | Q1 2020: -$5.68 million | Q2 2020: -$4.66 million | Q3 2020: -$5.61 million | Q1 2021: -$5.37 million | Q2 2021: -$5.08 million | Q3 2021: -$6.47 million | Q1 2022: -$5.16 million | Q2 2022: -$7.85 million | Q3 2022: -$9.80 million | Q1 2023: -$11.58 million | Q2 2023: -$15.64 million | Q3 2023: -$14.35 million | Q1 2024: -$9.60 million | Q2 2024: -$12.42 million | Q3 2024: -$12.60 million | Q1 2025: -$16.64 million | Q2 2025: -$7.50 million | Q3 2025: -$5.69 million.
- Over the full 16 years of available data (2010 to 2025), Actinium Pharmaceuticals, Inc.'s Operating Income Loss has declined by 139,027.9%.
- Historical annual values: Fiscal year 2025: -$36.25 million | Fiscal year 2024: -$42.12 million | Fiscal year 2023: -$51.92 million | Fiscal year 2022: -$34.10 million | Fiscal year 2021: -$24.96 million | Fiscal year 2020: -$22.39 million | Fiscal year 2019: -$22.07 million | Fiscal year 2018: -$23.83 million | Fiscal year 2017: -$26.91 million | Fiscal year 2016: -$26.85 million | Fiscal year 2015: -$24.83 million | Fiscal year 2014: -$22.48 million | Fiscal year 2013: -$6.59 million | Fiscal year 2012: -$7.95 million | Fiscal year 2011: -$3.28 million | Fiscal year 2010: -$26.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: